Esperion Therapeutics, Inc.
Industry
- Pharmaceuticals
- Vaccines
- Biotechnology
Latest on Esperion Therapeutics, Inc.
Micro Labs looks set to wait almost until patent expiry to launch its proposed generic version of Esperion’s Nexletol (bempedoic acid) after settling patent-infringement litigation with the originator
The 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th
The 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th
NewAmsterdam Pharma Company has added more evidence that its CETP inhibitor obicetrapib is effective at lowering low-density lipoprotein cholesterol (LDL-C) in patients at risk of cardiovascular disea